Elan receives notification of Tysabri review

Pharmaceutical company Elan and Biogen Idec have received notification from the US Food and Drug Administration (FDA) that the Peripheral and Central Nervous System Drugs Advisory Committee will review drug Tysabri for the treatment of multiple sclerosis on March 7.

Elan and Biogen Idec were forced to withdraw the drug last February after some patients using it developed a potentially fatal brain disease, progressive multifocal leukoencephalopathy (PML). Three confirmed cases of PML were reported, two of which were fatal.